Horizon Therapeutics PLC (HZNP): Price and Financial Metrics
GET POWR RATINGS... FREE!
HZNP POWR Grades
- HZNP scores best on the Sentiment dimension, with a Sentiment rank ahead of 90.78% of US stocks.
- HZNP's strongest trending metric is Quality; it's been moving up over the last 179 days.
- HZNP ranks lowest in Momentum; there it ranks in the 8th percentile.
HZNP Stock Summary
- HZNP has a market capitalization of $24,051,085,991 -- more than approximately 89.32% of US stocks.
- HZNP's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 251.19 -- higher than 89.87% of US-listed equities with positive expected earnings growth.
- With a year-over-year growth in debt of 156.26%, Horizon Therapeutics Public Ltd Co's debt growth rate surpasses 92.91% of about US stocks.
- Stocks that are quantitatively similar to HZNP, based on their financial statements, market capitalization, and price volatility, are NICE, TRIP, STAA, TWOU, and ETSY.
- HZNP's SEC filings can be seen here. And to visit Horizon Therapeutics Public Ltd Co's official web site, go to www.horizontherapeutics.com.
HZNP Valuation Summary
- In comparison to the median Healthcare stock, HZNP's price/sales ratio is 15.42% lower, now standing at 9.6.
- HZNP's EV/EBIT ratio has moved up 65.2 over the prior 123 months.
- Over the past 123 months, HZNP's price/sales ratio has gone down 35.9.
Below are key valuation metrics over time for HZNP.
HZNP Growth Metrics
- Its 5 year net cashflow from operations growth rate is now at -3.61%.
- Its 2 year net cashflow from operations growth rate is now at 54.81%.
- The 3 year net cashflow from operations growth rate now stands at -2.37%.
The table below shows HZNP's growth in key financial areas (numbers in millions of US dollars).
|Date||Revenue||Operating Cash Flow||Net Income to Common Stock|
HZNP's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- HZNP has a Quality Grade of C, ranking ahead of 61.77% of graded US stocks.
- HZNP's asset turnover comes in at 0.385 -- ranking 123rd of 681 Pharmaceutical Products stocks.
- VNDA, NEOG, and CEMI are the stocks whose asset turnover ratios are most correlated with HZNP.
The table below shows HZNP's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
HZNP Stock Price Chart Interactive Chart >
HZNP Price/Volume Stats
|Current price||$79.76||52-week high||$120.54|
|Prev. close||$82.50||52-week low||$78.85|
|Day high||$82.34||Avg. volume||1,892,587|
|50-day MA||$90.57||Dividend yield||N/A|
|200-day MA||$101.02||Market Cap||18.34B|
Horizon Therapeutics PLC (HZNP) Company Bio
Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.
Most Popular Stories View All
HZNP Latest News Stream
|Loading, please wait...|
HZNP Latest Social Stream
View Full HZNP Social Stream
Latest HZNP News From Around the Web
Below are the latest news stories about Horizon Therapeutics Public Ltd Co that investors may wish to consider to help them evaluate HZNP as an investment opportunity.
Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
DUBLIN, February 23, 2022--Horizon Therapeutics announces the initiation of a Phase 3 trial (OPTIC-J) in Japan evaluating teprotumumab for the treatment of active TED.
Horizon Therapeutics Public Limited Company (HZNP) stock has been hot recently, gaining 8.0% over the past month.
DUBLIN, February 21, 2022--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will present at the following conference in March:
Horizon Therapeutics plc (NASDAQ: HZNP ) shared results from a new analysis showing treatment with Uplinza reduced the severity of attacks in people with Neuromyelitis Optica Spectrum Disorder (NMOSD) . The data will be presented at the 48th Annual Meeting of the North American Neuro-Ophthalmology Society. NMOSD is a neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord, brain, and … Full story available on Benzinga.com
Horizon Therapeutics (HZNP) said a new analysis showed that Uplizna reduced the severity of attacks and levels of key disease-related biomarkers in people with Neuromyelitis…
HZNP Price Returns
Continue Researching HZNPWant to do more research on Horizon Therapeutics Public Ltd Co's stock and its price? Try the links below:
Horizon Therapeutics Public Ltd Co (HZNP) Stock Price | Nasdaq
Horizon Therapeutics Public Ltd Co (HZNP) Stock Quote, History and News - Yahoo Finance
Horizon Therapeutics Public Ltd Co (HZNP) Stock Price and Basic Information | MarketWatch